Land Dispute! NMC Halts MBBS Admission at Kanyakumari Medical Mission Research Centre

Chennai: Taking note of the ongoing land dispute regarding the construction site of Kanyakumari Medical Mission Research Centre, the National Medical Commission (NMC) has put the Letter of Permission (LoP) granted to the medical college for MBBS admission.

Referring to the directions issued by the NMC in this regard, the Selection Committee of the Directorate of Medical Education and Research (DMER), Tamil Nadu has now withdrawn the seats shown in the seat matrix and during the 1st Round of Counselling.

“Based on the above communication the seats shown in the seat matrix and during the 1st Round of counselling for Kanyakumari Medical Mission Research Centre (State Private University) is hereby withdrawn and accordingly the 1st round counselling will be done and the results will be published at the earliest,” the DMER mentioned in a notice issued on 30.08.2024.

Tamil Nadu DMER issued this notice after receiving a notice in this regard from the Apex Medical Commission on 30.08.2024. NMC informed that Kanyakumari Medical Mission Research Centre had submitted its application for the establishment of new medical college for the Academic Year 2024-2025 for the MBBS course.

After the due process, the Medical Assessment & Rating Board (MARB) granted the college the Letter of Permission (LoP) dated 04.07.2024 for 50 seats. Further, the college was granted LoP for 100 seats in accordance with the decision of the first Appeal Committee i.e. National Medical Commission vide LoP dated 10.08.2024.

Meanwhile, NMC received a plea filed by M/s. Michael Builders & Developers Pvt. Ltd before the Delhi High Court. The plea was filed against the Trust and the College, alleging that the land on which the Medical College was constructed was disputed.

“In view of the above facts it has been decided that the LOP dated 04.07.2024 & 10.08.2024 issued to the college will be on hold till further notice from NMC and it will also be the subject of the outcome of the decision in the instant writ petition,” NMC mentioned in the letter directed to TN DMER.

Asking the State not to admit students to the college during the ongoing counselling till further orders, the letter further added, “Accordingly, you are requested to ensure that students will not be admitted to the college during the ongoing counselling till further communication from NMC.”

Based on the communication issued by NMC, the Selection Committee of TN DMER has now withdrawn the seats shown in the seat matrix and during the 1st Round of Counselling for the medical college.

To view the notice, click on the link below:

https://medicaldialogues.in/pdf_upload/withdrawal-of-mbbs-seats-250522.pdf

Also Read: Tamil Nadu Releases Rank List For MBBS, BDS 2024 Admissions, Cut-off Likely To Increase

Powered by WPeMatico

MBBS Curriculum: NMC Releases CBME Guidelines 2024, Details

New Delhi: Laying down the latest guidelines for the MBBS course, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has now published the final Competency-Based Medical Education Regulations 2024.

These new guidelines include objectives of the Indian Graduate Medical Training Programme, National Goals with respect to Indian Medical Graduates, Institutional Goals, Goals for the Learner, the Competency-Based Training Programme for Indian Medical Graduates, the roles of leader and member of the healthcare team, system and the role of the communicator with patients, families, colleagues and community, the role of lifelong learner committed to continuous improvement of skills and knowledge, and of a professional who is committed to excellence, is ethical, responsive and accountable to patients, the profession and community etc.

Apart from these, the Curriculum at length discussed the subject goals of Phase 1 subjects including Anatomy, Physiology, and Biochemistry, Phase 2 subjects including Pathology, Microbiology, and Pharmacology, Phase III Part 1 subjects including Forensic Medicine and Toxicology, Community Medicine, Oto-Rhinolaryngology, Ophthalmology, Phase III Part II subjects including General Medicine, Pediatrics, Dermatology, Venereology, Psychiatry, General Surgery, Obstetrics and Gynaecology, Orthopaedics, Anaesthesiology, and Radiodiagnosis.

Further, the final CBME Curriculum has also discussed the phase-wise training and time distribution for professional development. It includes training period and time distribution, the distribution of 4.5 years period, and phase-wise distribution of teaching hours. It also discussed the new teaching/learning elements including the foundation course, early clinical exposure, electives, Professional Development including Attitude, Ethics and Communication Module (AETCOM), Alignment and integration (AIT) teaching, Learner-doctor method of clinical training (Clinical Clerkship), Assessment etc.

The duration of 4.5 years of the MBBS course has been divided into three phases. The tenure of Phase I or the First Professional phase is 12 months including a Foundation Course of two weeks and university exams. Similarly, the 12-month-long Phase II or Second Professional phase includes university examinations. In the case of Phase III, the tenure is 30 months long and it is divided in Third Professional Part I and Part II. Among these, Third Professional Part I is 12 months long and it includes university exams. Phase III Part II is 18 months long and it includes University exams.

Regarding the Assessment and eligibility to appear for Professional examinations, the new CBME curriculum discussed attendance, internal assessment, certifiable competence achieved, university examinations, the appointment of examiners, etc.

The regulations also include AETCOM Modules for teaching and assessment, the time distribution of MBBS Teaching & Examination schedule, proposed time distribution of MBBS teaching and Examination schedule, distribution of subjects in each Professional Phase, teaching hours during Foundation Course, Distribution of subject-wise teaching hours for Phase I, Phase II and Phase III (Part I and II) MBBS, clinical posting schedules in weeks, learner-doctor programme (clinical clerkship), marks distribution for various subjects for University Annual Examinations, suggested format for a theory paper, and Phase I and Phase II alignment.

The new regulations also contain the curriculum for the Family Adoption Programme. The curriculum discussed in detail about targets to be achieved by the MBBS students in their first, second, and third professional year of the course, Phase wise competencies to be achieved through the FAP, Log Book for Family Adoption Programme. This log book includes the name of the college, university, name of the student, roll number, address of community for FAP, number of adopted families, names of head of household of adopted families, dates of screening camp, name of faculty guide/mentor, names of PGs/SRs Guide/Mentor, and names of para-clinical staff guide/mentor.

The regulations also include the guidelines for manpower requirement for research facilities in a medical college, and the guidelines regarding admission of students with “specified disabilities” under the Rights of Persons with Disabilities Act, 2016 with respect to admission in MBBS course.

To view the CBME 2024 Guidelines, click on the link below:

https://medicaldialogues.in/pdf_upload/cbme-guidelines-2024-250434.pdf

Also Read: Final regulations on MBBS Curriculum released by NMC

Powered by WPeMatico

Medanta achieves National Recognition as Active Emerging Lung Transplant Centre in North India

Gurugram: Medanta Gurugram has become the first hospital to receive the recognition of ”Active Emerging Lung Transplant Centre in North India” from the Ministry of Health and Family Welfare (MoHFW) and the National Organ and Tissue Transplant Organisation (NOTTO). 

Awarded to the Medanta Institute of Lung Transplantation, led by Dr Arvind Kumar, the prestigious title is a testament to the hospital’s commitment to advancing specialised lung care and contributing to the broader goal of promoting organ donation and transplantation awareness in India.

Dr Arvind Kumar, Chairman, Institute of Lung Transplantation, Medanta Gurugram, said, “Lung transplantation represents the pinnacle of hope for those battling end-stage lung diseases, which have emerged as the third leading cause of mortality worldwide, including in India. At Medanta, we have relentlessly pursued excellence in establishing and advancing our lung transplant facility, aiming to deliver unparalleled outcomes for patients across North India.

Also Read:Medanta Chairman Dr Naresh Trehan honoured as one of ‘Seven Legends’ by International Congress of Cardiac Surgery in Greece

Our dedication has culminated in a remarkable achievement: Since the programme’s inception in November 2022, the Medanta Lung Transplantation Institute has successfully completed 15 lung transplant procedures—the highest number of cases done by any lung transplantation centre within the first 18 months of operation. This exceptional feat, coupled with our sustained initiatives to promote organ donation awareness, has been instrumental in earning this prestigious recognition from the Government of India and NOTTO. Our success is further validated by Medanta’s consistent performance and significant case volume, both of which were key factors in our evaluation.

The comprehensive expertise of our multidisciplinary team, bolstered by unwavering support from our leadership, particularly Dr. Naresh Trehan, have been pivotal to our success. This recognition not only honours our past achievements, but also fuels our commitment to pushing the boundaries of lung care, offering renewed hope to patients, and setting new benchmarks in transplant medicine.”

Lung transplantation stands as a critical, life-saving procedure for patients with end-stage lung diseases who have exhausted all other treatment options. For these individuals, a transplant often represents their last hope for survival without which patients’ life expectancy is measured in months rather than years. Successful lung transplantation can significantly extend life expectancy and dramatically improve quality of life.

According to the International Society for Heart and Lung Transplantation, the median survival rate for lung transplant recipients is now 6.7 years, with many patients living 10 years or more post-transplant. Some recipients have even survived beyond 20 years with their transplanted lungs. This stark difference underscores the vital importance of lung transplantation in not only extending lifespan but also in restoring patients’ ability to breathe freely, engage in daily activities, and enjoy a fuller life.

Speaking on the recognition, Dr Naresh Trehan, Chairman and Managing Director, Global Health Limited (Medanta), said, “This recognition reflects our unwavering commitment to advancing medical science and improving patient outcomes. At Medanta, we have built an ecosystem that fosters innovation, pioneers cutting-edge treatments, and delivers exceptional results.

Our lung transplant programme exemplifies this ethos. We have established rigorous protocols for medical training, and collaborated with some of the best institutions to drive public awareness to address the critical challenge of organ availability in North India. As we refine our processes and expand our capabilities, we remain focused on our core mission: resolving complex cases and improving patient outcomes through enhanced safety, standardized care, and tailored, cutting-edge therapies. Looking ahead, we envision Medanta leading the charge in making advanced lung care more accessible in India.”

Speaking about the rise in lung transplants in India, Dr Kumar, said, “The rise in number of lung transplants in India can be attributed to factors such as greater awareness, improved access to advanced facilities, trained manpower, cutting-edge technology, and the development of specialized programmes across various hospitals.”

Increased awareness among physicians, patients, and the broader healthcare ecosystem has also played a crucial role. “A decade ago, only a few cases were performed annually. But today, more than 100 cases are done each year, which is a remarkable increase. This speaks of our improved medical prowess and represents new hope for patients and their loved ones.”

By fostering an environment that drives clinical excellence and promotes the use of the most cutting-edge technology, Medanta is poised to set new standards in organ transplantation. As the hospital continues to address the challenges of organ availability through awareness campaigns on donation and patient outcomes, its clinical contributions are set to offer renewed hope and life-saving solutions to those afflicted by end-stage lung diseases.

Also Read:Medanta develops AI-enabled Penumbra Lightning technology, successfully treats 25 pulmonary embolism patients

Powered by WPeMatico

FDA authorizes Novavax’s updated COVID vaccine targeting JN.1 strain

Bengaluru:  The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax’s COVID shot.

The updated vaccine is authorized for use in individuals 12 years of age and older and will target the JN.1 strain of the virus.
Shares of the company were up 2.2 per cent in extended trading after closing 8.6 per cent higher.
“Today’s authorization provides an additional COVID-19 vaccine option,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
Doses are on track to be available as early as the end of next week, the company said in an emailed response.
Read Also: Lung cancer drug: Natco Pharma submits ANDA for generic version of Novartis Tabrecta
The updated vaccine targets the ‘parent strain’ of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1, said CEO John Jacobs.
Earlier this month, the health regulator approved updated COVID-19 vaccines made by Pfizer and Moderna targeting the KP.2 variant.
JN.1 was the dominant strain in the United States earlier this year. While it is no longer as prevalent, it is estimated to account for 0.2% of cases over a two-week period ended Aug. 31, the Centers for Disease Control and Prevention’s data showed.
The KP.2 subvariant, on the other hand, is estimated to account for 3.1 per cent, with KP.3.1.1 now becoming dominant at 42.2%.
In June, the health regulator asked COVID vaccine makers to target the KP.2 strain for 2024-25 COVID-19 vaccines.
Novavax’s traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA – Moderna’s Spikevax and Comirnaty, which is jointly developed by Pfizer and BioNTech.
COVID-19-related hospitalizations and deaths have increased over the past three months in the United States. Demand for the shots, however, has fallen sharply since the peak of the pandemic.
Novavax expects overall demand for COVID vaccines in the United States to remain similar to last year, but anticipates its own performance to be better, it said earlier this month.
Read Also: Zydus Lifesciences bags USFDA nod for Scopolamine Transdermal System 1 mg/3 days

Powered by WPeMatico

Chennai Doctor arrested for sending obscene photos, messages to ex-classmate

Chennai: A 27-year-old doctor working at a private medical college in Tiruvallur has been recently arrested for allegedly sending obscene messages and pictures to a woman doctor at a private hospital in Vadapalani.  

According to the police, the female doctor is the former classmate of the accused who studied together at the Sri Lakshmi Narayana Institute of Medical Sciences in Puducherry from 2015 to 2021.

The complainant was receiving morphed intimate images of herself and her husband along with threatening messages that included threats to rape her. Following this, she informed her husband also a doctor regarding this. The complainant and the male doctor got married a year ago. 

Also read- ‘Kicked, punched, tortured’: 1st-year PGIMS BDS student alleges assault, harassment by MD anatomy medico for past 7 months, accused arrested

As per The Hindu news report, the incident took place in May this year when the complainant began receiving altered images and obscene messages on her Instagram handle. Following this, the complainant’s husband blocked the user on Instagram. However, the accused continued to send such messages and pictures to her.

It took a turn when the husband received morphed intimate pictures of his wife and himself and even allegedly threatened to assault his wife sexually. Later, the husband contacted the sender to confront him but only got abused by him.

The doctor couple then approached the cyber police to file a complaint against the person. Based on the complaint, the police registered a case under sections 78(2), 351(2), 66(D), and 67(A) of the IT Act and launched an investigation. 

After tracing the social media ID of the sender, the police identified the accused and arrested him from the private medical college and hospital where he was working. An investigation in this regard is underway. 

Also read- Mumbai Doctor duped of Rs 28 lakh by Fake Irish Surgeon on LinkedIn

Powered by WPeMatico

Compulsory Social Responsibility Service for 1 Year, Rs 10 Lakh Penalty for leaving India: Maharashtra notifies policy for MBBS, BDS candidates

Mumbai: MBBS/BDS students getting admitted to Government/Municipal Corporation colleges, Govt. Aided/Unaided Private Institutes in Maharashtra or those who are availing reimbursement/Scholarship from various Government Departments will have to undergo a compulsory social responsibility service for one year, after the completion of their mandatory internship.

Additionally, such students will have to sign an undertaking assuring that he/she will not leave India within five years from the date of obtaining their degree. Students will have to pay Rs 10 lakh as a penalty for violating this condition.

This compulsory social responsibility service is not applicable for the candidates who are not availing reimbursement of fees/Scholarships, clarified the Information Brochure of Preference System for admission to Health Science Courses in State Government/Corporation/Private & Minority Colleges, released by Maharashtra State CET Cell.

Compulsory Social Responsibility Service: 

The Brochure clarified that as per Government Resolution (G.R. No. MED 1007/C.R.490/07/Edu-2 dated 8th Feb 2008, G.R. No. MED 1021/C.R.128/21/Edu-2, dated 13th June 2022, and any other G.R. issued in this regard from time to time), “candidates joined against the seats of Government/Municipal Corporation colleges for admission to MBBS/BDS Courses either through GOI nominee, All India quota and State quota through NEET UG 2022 onwards will be required to sign a social responsibility service to compulsorily serve the Government of Maharashtra or local self government or Defence services for a period of one year, after the completion of internship.”

Apart from this, such candidates will be required to sign an undertaking to the effect that he/she will not leave India within a period of five years from the date of obtaining the degree, otherwise, he/she will have to pay Non-Refundable Rs. 10,00,000/- (Rs.Ten lacs only) as penalty.

Social Responsibility Service for Private Unaided MBBS Courses: 

As per Government Resolution (G.R. No. MED 1016/C.R.345/16/Edu-2 Dated: 05/01/2018 and G.R. No. MED 1021/C.R.128/21/Edu-2, dated 13th June 2022), “the candidate who has taken admission to MBBS course in Govt. aided / Unaided Private institute through NEET UG 2022 and is availing reimbursement / Scholarship from various departments like Tribal Welfare Department, Social Justice And Special Assistance Department, Other Backward Bahujan Welfare Department and Medical Education & Drug Department will be required to sign a social responsibility service to compulsorily serve the Government of Maharashtra for a period of one year, after the completion of internship,” stated the Brochure.

However, it clarified that “The Candidate who are not availing reimbursement of fees / Scholarship, the said social responsibility service is not applicable.”

The Directorate of Medical Education Research, Mumbai and Directorate of Health Services, Government of Maharashtra will implement the allotment of social responsibility service, the State CET cell mentioned in the Information Brochure.

Penalty for Lapse of MBBS/BDS seats: 

Candidates leaving the MBBS/BDS seats at Government/Government Aided/Corporation Medical/Dental College will be liable to pay Rs 10 lakh as penalty if they join the seats during the last round or after the last round of admission and those who fails to complete the course after enrolment. 

“Any candidate responsible for lapse of MBBS/BDS seat at Government/Government Aided/Corporation Medical/Dental College will have to pay a Non Refundable penalty of Rs.10,00,000/- (Rupee Ten Lacs Only). This penalty is applicable to all those candidates who do not join during last round or cancel a seat after last round of admission. This penalty is also applicable to any candidate resigning a seat after cut off date for MBBS/BDS courses or also fails to complete the course, irrespective of admission quota of the candidate,” the Brochure states.

However, for Lapse of seat at Government/Government Aided/Private unaided Colleges (Ayush Course), the candidates will have to pay Rs 3 lakh as penalty for leaving the seat.

In this regard, the Brochure mentions, “Any candidate who resigns a seat after cut off date from Government/Government Aided/Private unaided College (Ayush Course) will have to pay Rs. 3,00,000/- (Rs. Three lakhs only) as penalty.”

To view the Information Brochure for NEET UG 2024 Admissions in Maharashtra, click on the link below:

https://medicaldialogues.in/pdf_upload/maha-cet-cell-neet-ug-brochure-250389.pdf

Also Read: 1-year Compulsory Bond Service, Rs 15 Lakh Penalty: Karnataka Bond policy for MBBS admissions

Powered by WPeMatico

AIIMS notifies on revised nomenclature for MSc Nursing course, details

New Delhi- Through a recent
notice, the All India Institute of Medical Sciences (AIIMS), New Delhi has informed about the revised nomenclature for a MSc Nursing course at AIIMS Jodhpur August 2024 Session.

As per the notice, the Open Round of Counseling of M.Sc. Nursing is scheduled to be held on September 04, 2024.

All the concerned
candidates seeking MSc Nursing Admission in All India Institute of Medical
Sciences (AIIMS), New Jodhpur College are advised to take note
of the following schedule: 

Corrigendum in Course Name for M.Sc. Nursing courses at AIIMS Jodhpur for Open Round
of Counseling scheduled to be held on 04th September, 2024

As per
the communication received from Registrar (Acad.), the Nomenclature of seat
position at AIIMS Jodhpur for open round of counseling August-2024 session
stands revised as per detail given below:

Sr. No

Previous
Name

Revised
Name

1

Pediatric Nursing

Medical Surgical Nursing

(Orthopedic Nursing)

The seat position
and other contents will remain same.

Also Read:No Further Online Seat Allotment Process for INI SS July 2024, Individual AIIMS, INIs may conduct stray vacancy round- Declares AIIMS Delhi

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/corrigendum-msc-1-aiims-250458.pdf

Powered by WPeMatico

Mumbai’s JJ Hospital gets Rs 728 crore for upgrading facilities

Mumbai: The state-run JJ Hospital is planning to undertake a major redevelopment project on its campus. The plan, estimated at ₹728 crores, aims to replace the aging residential quarters with luxury flats, marking a major shift in the hospital’s infrastructure and amenities. 

The deteriorating condition of the hospital’s on-campus residential quarters has long been a concern for its healthcare workers. Addressing these long-standing issues, the state government has approved an ambitious luxury redevelopment plan. This initiative will demolish the existing structures and replace them with modern high-rises. The new buildings will offer enhanced living conditions, featuring amenities such as podium parking, tranquil gardens, and a swimming pool, ensuring a significant lifestyle upgrade for the hospital staff.

Also Read: Mass Hadtaal: 8000 plus Maha Resident Doctors on Strike demanding stipend hike, hostel accommodation

The housing plan features several key components- a 22-storey tower dedicated to Class 1 and 2 staff, set to replace the 70-year-old Dhanvantari buildings. This modern tower will offer 40 generously-sized three-bedroom flats, each covering 1,152 square feet, and 110 two-bedroom flats of 872 square feet. Both types of residences will be designed to focus on comfort and luxury, ensuring an upgraded living experience for the staff.

The plan also features three 34-storey towers dedicated to Class 3 employees, providing 612 one-bedroom flats.

Additionally, four towers will be allocated for Class 4 staff, offering 816 modern one-bedroom flats. This comprehensive redevelopment aims to enhance living conditions across all employee levels.

According to The Indian Express, Dr Pallavi Saple, Dean of JJ Hospital, stated, “This transformation will not only improve living conditions but also boost the morale and productivity of our dedicated workforce.” She further stressed the urgent need for change, highlighting that the current quarters are so dilapidated that employees, particularly the elderly, are frequently forced to use external restrooms.

Also Read: JJ Hospital Dean Dr Pallavi Saple joins SC-formed National Task Force for Hospital Security

Recognizing the challenges faced by healthcare workers, the government’s approval of this luxury redevelopment plan highlights a commitment to enhancing the living environment in support of the hospital’s mission. The project blueprint has been developed by the Public Works Department (PWD). This comprehensive project aims to set a new benchmark in employee accommodation within the public healthcare sector.

This initiative not only reflects a growing trend towards modernizing essential facilities but also highlights the importance of investing in the well-being of those who play a crucial role in providing healthcare services.

Powered by WPeMatico

Drug distributors strike $300 million opioid settlement with US health plans

Boston: The three largest U.S. drug distributors have agreed to pay $300 million to resolve claims by health insurers and benefit plans that they helped fuel the deadly U.S. opioid epidemic, according to court papers filed on Friday.

The proposed class action settlement with McKesson Corp, Cencora Inc and Cardinal Health Inc was disclosed in a filing in federal court in Cleveland, Ohio, and requires a judge’s approval.
Those companies had previously agreed to pay $21 billion to resolve claims by state and local governments accusing them of having lax controls that allowed massive amounts of addictive painkillers to be diverted into illegal channels.
Paul Geller, a lawyer for the plaintiffs, said in a statement that Friday’s deal covered third-party payers like union funds that “largely paid for the overprescribed and overmarketed pills and for the treatment required when their plan beneficiaries inevitably suffered opioid use disorder.”
The distributors did not admit wrongdoing as part of the settlement. The $300 million will be paid 38.1% by McKesson, 30.9% by Cardinal and 31% by Cencora, which was previously known as AmerisourceBergen.
The case was among thousands that have been filed seeking to hold various drug makers, distributors and pharmacies responsible for a drug addiction epidemic that resulted in hundreds of thousands of overdose deaths nationally over the last two decades.
The litigation has resulted in more than $50 billion in settlements, largely with states and local government.
Also Read: Yogurt consumption can reduce type 2 diabetes risk: US FDA allows qualified health claim

Powered by WPeMatico

13 Formulations declared Not of Standard Quality as per data provided by states: CDSCO Drug Alert

New Delhi: In line with the ‘Not of Standard Quality’ data provided by states, the apex drug regulatory body, the Central Drug Standard Control Organisation (CDSCO), in its latest drug safety alert, has flagged 13 medicine batches for failing to qualify for a random sample test for July 2024.

The list of drugs declared not of standard quality includes Cephalexin Oral Suspension manufactured by Nestor Pharmaceuticals, Salbutamol Nebuliser Solution manufactured by Cotec Healthcare, Sodium Valproate Gastro Resistant Tablets manufactured by Unicare India, Cilader – 10 manufactured by Alventa Pharma, Bioglip 1Tablets manufactured IBN Herbals, Ciprofloxacin Hydrochloride manufactured by Wings Biotech, New improved Gentle Daily care Natural protein Shampoo manufactured by Himalaya Wellness, Irinotecan Inj.IP 100 mg vial Supplied by Kerala Medical Services Corporation, Vitamin B Complex tablet supplied by Kerala Medical Services Corporation Ltd, Chlorpromazine Tab Supplied by Kerala Medical Services Corporation, Fluorometholone eye drops IP manufactured by Cotec Healthcare, and Iron and Folic Acid Syrup manufactured by Jackson Laboratories.

Many factors contributed to the drug samples’ failure in the test, such as non-compliance with the IP requirements for the particular drug, failure of the dissolution test, pH, and some assays of the drug test, among others.

Furthermore, the alert noted that NSQ data was not received as per format and in EXCEL SHEET from State Drugs Licensing Authorities of Karnataka (PDF format), and Jharkhand (PDF format), for the month of July 2024.

In addition to the above, the alert mentioned, “State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Goa, Gujarat, Haryana, Himachal Pradesh, Manipur, Rajasthan, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry, , Telangana, Delhi, Uttarakhand, West Bengal, Andaman and Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of July 2024 as per DCG(I) Circular dated09.02.2024.”

NOT OF STANDARD QUALITY ALERT FOR THE MONTH OF July – 2024.

B. State Laboratories

S.No

Product/Drug Name

Batch No.

Manufacturing Date

Expiry

Date

Manufactured By

NSQ Result

Reported by

CDSCO Laboratory

1.

Cephalexin Oral Suspension IP

125/500

CHDA-01

04/23

09/24

Nestor Pharmaceuticals

Ltd, 11, Western

Extension Area,

Faridabad

It fails the test ‘Assay’ and

Descriptive part as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

2.

Salbutamol

Nebuliser

Solution BP 5

mg/ml

CHS-3085

06/23

05/25

Cotec Healthcare

Pvt.Ltd, N.H.No. 74, Roorkee , Dehradun , Highway, Kishanpur, Roorkee Uttarakhand

It fails the test ‘pH’ as per

BP

Drugs Testing

Laboratory

Thiruvananthapuram

3.

Sodium Valporate Gastro Resistant

Tablets IP 200 mg

SVT1140

09/23

08/26

Unicure India Ltd.,

C-21,22 &23, Sector-3, Noida-201301, Distt.

Gautam Budh Nagar

(UP)

It fails the test ‘Dissolution’ as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

4.

Cilader – 10

AGT30720

07/23

06/25

Alventa Pharma Ltd,

Vill, Kishanpura, Baddi- Nalagarh Road, tehsil,

baddi, Dist, Solan (HP)

It fails the test ‘Dissolution’ as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

5.

Bioglip 1

Tablets

BEL23021

09/23

08/25

IBN Herbals, Khasra No. 63, Vill, Juddi Kalan,

Baddi- 173205, Distt.

Solan (HP)

It fails the test ‘Dissolution’ as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

6.

Ciprofloxacin Hydrochloride

CPXT- 1016

10/23

09/26

Wings Biotech LLP,

43&44, HPSIDC,

It fails the test ‘Dissolution’

Drugs Testing

Laboratory

Tablets IP 500 mg

Ind.Area, Baddi- 173205 HP

as per IP

Thiruvananthapuram

7.

New improved Gentle Daily

care Natural

protein

Shampoo

B20240005 2

01/24

12/26

Himalaya Wellness

Company, No- 182,

Village Guru Majra, Tehsil, Baddi- 174101 Dist Solan (HP)

It fails the test for “heavy

metals as lead (Pb)” as per IS 7884:2023

Drugs Testing

Laboratory

Thiruvananthapuram

8.

Irinotecan Inj.IP 100 mg vial

D0368/23- 24

Supplied by Kerala

Medical Services

Corporation Ltd,

Thycaud P.O,

Thiruvananthapuram – 14

It fails the

tests

particulate

matter and

assay as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

9.

Vitamin B

Complex tablet

N.F.I.1

S0004/24-

25

Supplied by Kerala

Medical Services

Corporation Ltd,

Thycaud P.O,

Thiruvananthapuram – 14

The sample

does not

conform to IP standard with respect to the ‘Descriptive part’ for

tablets

Drugs Testing

Laboratory

Thiruvananthapuram

10.

Vitamin B

Complex tablet

N.F.I.1

S0003/24-

25

Supplied by Kerala

Medical Services

Corporation Ltd,

Thycaud P.O,

Thiruvananthapuram – 14

The sample

does not

conform to IP standard with respect to the ‘Descriptive part’ for

tablets

Drugs Testing

Laboratory

Thiruvananthapuram

11.

Chlorpromazine Tab IP 50 mg

D 0644/24- 25

Supplied by Kerala

Medical Services

Corporation Ltd,

The sample

does not

conform to IP

Drugs Testing

Laboratory

Thiruvananthapuram

Thycaud P.O,

Thiruvananthapuram – 14

standards. It

fails the

‘Descriptive

part’

12.

Fluorometholone Eye drops IP

CHE 3044

05/23

04/25

Cotec Healthcare

Pvt.Ltd, K.H.No. 593/1 Roorkee , Dehradun ,

Highway, Kishanpur, Roorkee- 247667

Uttarakhand

It fails the test ‘Assay’ as per IP

Drugs Testing

Laboratory

Thiruvananthapuram

13.

Iron & Folic Acid Syrup IP (JKMSCL Hospital Supply)

SY- 1641

01-08-2023

01-07-2025

Jackson Laboratories Pvt. Ltd 22-24, Majitha Road Bye Pass Amritsar

143001 , India

The sample

fails in the test for pH w.r.t

the sample

portion

received.

CFDL Jammu (J&K)

To View the official notice, click the below link:

https://medicaldialogues.in/pdf_upload/state-nsq-alert-for-the-month-of-july-2024-250196.pdf

Also Read:Submit details of adverse events reported: CDSCO Panel Tells GSK on Mepolizumab Powder for Solution for Injection

Powered by WPeMatico